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Abstract
Introduction Modern multidisciplinary cancer treatments
aim at obtaining minimal influence on patients’ quality of
life (QoL). The purpose of this study was to assess QoL
and correlate it with dose–volume parameters of organ at
risks (OARs) in patients who received adjuvant radiother-
apy for endometrial and cervical cancers.
Materials and methods We administered the EORTC
QLQ-C30 and EN24 or CX24 questionnaires to 124
patients, 100 with endometrial cancer and 24 with cervical
cancer treated with postoperative radiother-
apy ± chemotherapy in regular follow-up. Bladder func-
tion, fecal incontinence or urgency and sexual functioning
were investigated and correlated with dose–volume
parameters of OAR by multiple linear regression analysis.
This correlation was assessed by R2 value.
Results QoL was very high in the majority of patients
(82.3 % of patients). Few patients referred urinary incon-
tinence (3.2 %) or abdominal discomfort of high grade
(4.0 %). We found a significant correlation between blad-
der V40, i.e., absolute percentage of bladder volume that
received a dose of 40 Gy, and global health status
(p\ 0.05, R2 = 0.17), urinary urgency (p\ 0.05,
R2 = 0.24), urinary incontinence (p\ 0.05, R2 = 0.23)
and dyspareunia (p\ 0.05, R2 = 0.04). We found also a
correlation between global health status and mean dose to
vagina (p\ 0.05, R2 = 0.17) and between maximum dose
to lumbo-sacral plexus and abdominal pain (p\ 0.05,
R2 = 0.07).
Conclusions Women treated with surgery and adjuvant
radiotherapy for endometrial and cervical cancers have
good QoL with minimal limitations of daily activities. QoL
was correlated with dose–volume parameters such as
bladder V40, mean dose to vagina, maximum dose to tri-
gone and LSP.
Keywords Quality of life  Endometrial cancer  Cervical
cancers  Adjuvant radiotherapy  Dose–volume parameters
Introduction
Endometrial and cervical are the most common gyneco-
logic malignancies among women in Western countries.
Surgery, radiotherapy and chemotherapy are commonly
used and highly effective treatment modalities; however,
they can be associated with relevant adverse effects on
physical comfort, body image, sexual function and quality
of life (QoL). Assessment and measurement of cancer-re-
lated symptoms are a challenge because of complex
interactions between multimodality treatments and symp-
toms [1].
A higher incidence of late sequelae is reported after
postoperative radiation than after surgery alone, such as
abdominal pain, sexual symptoms and bladder dysfunc-
tions [2]. The use of multimodal treatment regimens is
associated with a rise of incidence of late effects within the
pelvis [3].
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There is paucity of data on long-term treatment effects
and the subsequent impact on QoL in gynecologic cancer
patients, and no studies have assessed the weight of the
treatment modalities in inducing worsening of QoL.
The purpose of this study is to assess QoL in endome-
trial and cervical cancer patients after surgery and adjuvant
radiotherapy ± chemotherapy in relation to radiation
dose–volume parameters of the organs at risk (OARs).
Materials and methods
We assessed QoL in 124 patients in regular follow-up for
endometrial and cervical cancers and previously treated by
a multidisciplinary approach including surgery and radio-
therapy ± chemotherapy. The institutional review board
approved the study.
Eligibility criteria were: previous radical hysterectomy
Piver II or type B–C, according to Querleu and Morrow
classification in case of laparoscopic surgery [4], no neo-
adjuvant chemotherapy, no post-surgical residual disease,
no postoperative major complications, indication to pelvic
external beam radiotherapy, minimum follow-up of 3 years
without disease relapse, performance status higher than 60
according to Karnofsky scale.
We report the patients’ characteristics and the treatment
modalities in Table 1. All patients were treated with
external beam radiotherapy (EBRT) with 3D conformal or
intensity-modulated radiation therapy (IMRT) to 45 Gy
(1.8 Gy/fx) on the pelvis and the upper half of vagina or
45 Gy (1.8 Gy/fx) on the pelvis and 50 Gy (2.0 Gy/fx) on
the upper half of vagina in case of simultaneous integrated
boost (SIB).
According to guidelines, we completed adjuvant treat-
ment with vaginal pulsed dose rate brachytherapy (BRT) in
85 cases [5]. Clinical target volume (CTV) contours were
based on the guidelines from the Radiation Therapy
Oncology Group (RTOG) and the Gynecologic IMRT
Consortium [6]. For BRT, we used the guidelines of the
European Society for Therapeutic Radiology and Oncology
(GEC-ESTRO) [7]. In particular, we contoured bladder,
trigone, vagina and rectum according to the RTOG atlas [8]
and LSP according to the guideline proposed by Yi et al.
[9]. In all treatment plans, dose constraints for all OARs
were strictly respected. We report values of the main dose–
volume parameters for EBRT and BRT in Table 2.
Acute genito-urinary and gastro-intestinal toxicity
according to the RTOG scale are reported in Table 3 [10].
Forty-five out of 100 patients with endometrial cancer
and all patients with cervical cancer were treated with
cisplatin or carboplatin regimen-based chemotherapy con-
comitantly to radiotherapy.
Self-reported QoL was assessed using the questionnaires
EORTC QLQ-C30 and QLQ-CX24 or QLQ-EN24. The
EORTC QLQ-C30 (version 3.0) consists of 30 items
measuring functioning (physical, role, emotional, social
functioning and a global health scale) and symptoms.
Global health status was evaluated with the item 30 of the
EORTC QLQ-C30 in which patients had to assign a score
from zero (low QoL) to seven (high QoL).
All patients completed also the EORTC QLQ-CX24 or
QLQ-EN24 questionnaire specific for cervical and
endometrial cancer patients. These disease-related ques-
tionnaires contain 24 items summarized in three scales:
Table 1 Clinical and treatment characteristics of the 124 patients
Characteristics Number of patients %
KPS (n = 124)
70 12 9.7
80 65 52.4
90 45 36.3
100 2 1.6
BMI (n = 124)
18.5–24.9 107 86.3
25.9–29.9 15 12.1
30.0–34.9 2 1.6
Primitive cancer
Endometrial 100 80.6
Cervical 24 19.4
Endometrial cancer (n = 100) T stage (TNM seventh edition)
IA 11 11
IB 34 34
II 48 48
IIIA 4 4
IIIC1 3 3
Cervical cancer (n = 24)
T stage (TNM seventh edition)
IB2 11 45.8
IIA 8 33.3
IIB 3 12.5
IIIA 2 8.3
Radiotherapy (n = 124)
Adjuvant EBRT 45 36.3
Adjuvant EBRT ? BRT 79 63.7
EBRT (n = 124)
Conformal 3D radiotherapy 22 17.7
IMRT with SIB 79 63.7
IMRT 23 18.5
KPS, performance status according to Karnofsky scale; BMI, body
mass index; EBRT, external beam radiotherapy; BRT, brachytherapy;
IMRT, intensity-modulated radiotherapy; SIB, simultaneous inte-
grated boost
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symptoms experience, body image and sexual/vaginal
functioning.
To assess bladder and intestinal functions, we analyzed
items related to urinary frequency, incontinence/urgency
and fecal incontinence. We also analyzed items related to
abdominal pain and sexual activity, in particular dyspare-
unia. For all these items, patients could assign a score from
one (no problems) to four (problems that cause
discomforts).
The QoL items were subsequently correlated with
dose–volume parameters of OARs, and the possible rela-
tionships were analyzed by multiple regression analysis. A
p value of\0.05 was considered as statistically significant.
Multiple linear regression analysis was used to assess also
the association between two or more independent variables
and a single continuous dependent variable. The magni-
tude and the goodness of fit were assessed by adjusted R2
value.
Results
Based on selection criteria, we enrolled 124 out of 145
consecutive patients in regular follow-up of 3.5–11.5 years
(median 4.5 years) after surgery and adjuvant radiotherapy
for endometrial and cervical cancers. At treatment time,
median age was 67.4 years (range 29–86) and median BMI
was 23.7 (range 19.8–27.3).
Table 2 Values (range) of
dose–volume parameters of
OAR
EBRT (n = 124) BRT (n = 79)
Rectum
Volume 50.6 cc (20.2–90.3) 47.4 cc (19.8–60.2)
Mean dose 40.3 Gy (34.7–42.7) 3.0 Gy (0.1–5.3)
Maximum dose 47.4 Gy (42.8–54.2) 7.8 Gy (3.2–13.8)
V40 59.7 % (32–82) Not applicable
Bladder
Volume 159.8 cc (78.6–588.9) 150.1 cc (148.2–153.4)
Mean dose 39.3 Gy (32.2–49.4) 2.8 Gy (1.3–5.2)
Maximum dose 47.5 Gy (44.8–54.4) 8.9 Gy (5.0–12.9)
V40 54.9 % (43–79) Not applicable
Bladder trigone
Volume 3.4 cc (2.1–5.9) 3.5 cc (3.2–6.4)
Mean dose 42.1 Gy (35.9–44.8) 3.2 Gy (2.4–6.1)
Maximum dose 44.4 Gy (42.2–48.6) 9.1 Gy (5.3–13.2)
Vaginal cuff
Volume 45.3 cc (37.3–58.9) 44.8 cc (35.3–53.2)
Mean dose 41.1 Gy (36.7–43.8) 8.6 Gy (5.4–12)
Maximum dose 46.0 Gy (40.1–51–0) 11.4 Gy (8.6–12.3)
Lumbo-sacral plexus Not applicable
Volume 131.5 cc (106.5–189.4)
Mean dose 37.6 Gy (32.0–42.6)
Maximum dose 46.3 Gy (43–48.6)
V40 57.8 % (52–64)
EBRT, external beam radiotherapy; BRT, brachytherapy; V40, absolute percentage of bladder volume that
received a dose of 40
Table 3 Acute urinary (GU) and gastro-intestinal (GI) according to
RTOG scale
Toxicity Number of patients %
Acute GU (n = 124)
G0 24 19.4
G1 63 50.8
G2 37 29.8
G3 0 0
G4 0 0
Acute GI (n = 124)
G0 65 52.4
G1 47 37.9
G2 12 9.6
G3 0 0
G4 0 0
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Compliance to questionnaires was 100 % except for
questions about sexual/vaginal functioning that were
answered by 85/124 patients (65.4 %).
We report the answers to the EORTC questionnaires
items in Table 4. We did not observe any statistical cor-
relations between QoL parameters and acute toxicities. We
summarize the results of the correlation between QoL and
dose–volume parameters in Table 5.
According to multiple linear regression analysis, bladder
V40, i.e., the absolute percentage of bladder volume that
received at least 40 Gy, was significantly associated with
worsening of global health status (p\ 0.001). Mean dose
to the vagina was significantly associated with worsening
of global health status (p = 0.03) with an adjusted R2 value
of 0.17 (Fig. 1).
Bladder V40 (p\ 0.001) and mean dose to vagina
(p = 0.02) were correlated with urinary urgency with an
adjusted R2 value of 0.24, meaning an increasing urinary
urgency with increase in bladder V40 and mean dose to
vagina (Fig. 2). Bladder V40 was correlated also with
urinary incontinence (p\ 0.001) with an adjusted R2 value
of 0.24, meaning that the parameter V40 can explain the
worsening of 24 % of urinary incontinence variance
(Fig. 3).
We did not find any statistical correlation between
global health status, bladder discomforts and dose to the
trigone.
Table 4 Answers to EORTC questionnaires
Items Number of
patients
%
Global health status (n = 124) QLQ-C30
1–3 (low QoL) 22 17.7
4–5 42 33.9
6–7 (high QoL) 60 48.4
Bladder urgency (n = 124) EN-24 or CX-24
1–2 (no symptoms) 108 87.1
3–4 (a lot of symptoms) 16 12.9
Bladder incontinence (n = 124) EN-24 or CX-24
1–2 (no symptoms) 120 96.8
3–4 (a lot of symptoms) 4 3.2
Rectal discomforts (n = 124) EN-24 or CX-24
1–2 (no symptoms) 124 100
3–4 (a lot of symptoms) 0 0
Abdominal pain (n = 124) EN-24 or CX-24
1–2 (no symptoms) 119 96.0
3–4 (a lot of symptoms) 5 4.0
Dyspareunia (n = 85) EN-24 or CX-24
1–2 (no symptoms) 80 94.1
3–4 (a lot of symptoms) 5 5.9
Table 5 Multiple linear regression analysis
Variable p value R2 value
Global health status (QLQ-C30)
V40 bladder 0.00008 0.17
Mean dose vagina 0.032
Urinary urgency (EN-24 or CX-24)
V40 bladder 0.000055 0.24
Maximum dose vagina 0.016924
Urinary incontinence (EN-24 or CX-24)
V40 bladder 0.0000002 0.24
Abdominal pain (EN-24 or CX-24)
Maximum dose LSP 0.008377 0.07
Dyspareunia (EN-24 or CX-24)
V40 bladder 0.035381 0.04
LSP, lumbo-sacral plexus; V40 bladder, absolute percentage of
bladder volume that received a dose of at least 40 Gy
Fig. 1 Global health status and V40 bladder/mean dose to vagina
(DM vagina)
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No correlation was found between gastro-intestinal
symptoms (fecal incontinence and urgency) and dose–
volume parameters. Conversely, a significant correlation
between maximum dose to LSP and abdominal pain
(p = 0.008, R2 = 0.07) was observed (Fig. 4).
We found a statistical correlation between dyspareunia
and bladder V40 (p\ 0.05) but not with vaginal radiation
dose. Goodness of this fit is poor, being the adjusted R2
value 0.04, meaning that this relationship is able to explain
only of 4 % dyspareunia variance.
We did not find any statistical correlation of BRT doses
to bladder or rectum with QoL in terms of gastro-intestinal
or genito-urinary symptoms.
In this analysis, we did not find any significant differ-
ence in terms of QoL items and dose–volume parameters
between patients with endometrial or cervical cancers,
patients treated with EBRT or EBRT ? BRT and also
between patients treated with adjuvant radiotherapy alone
or radiochemotherapy.
Discussion
Since treatment of the large majority of patients (80–95 %)
with endometrial and cervical cancer is curative, it is
important to pay attention on its impact of long-term QoL
and on the interventions that could improve QoL itself. As
a matter of fact, gynecologic cancer survivors commonly
report late effects [11]. The level of health-related QoL
should become a central element within therapeutic stan-
dards in clinical practice.
Fig. 2 Correlation between self-reported urinary urgency and V40 bladder/mean dose to vagina (DM vagina)
Fig. 3 Correlation between incontinence and V40 bladder Fig. 4 Correlation between abdominal pain and maximum dose to
LSP
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The relevance of the role of QoL in gynecologic cancer
has increased after the publication of PORTEC-2 study.
This study showed that patients treated by BRT had less
morbidity and better QoL compared to those who received
EBRT [12].
We decided to analyze a homogeneous group of
endometrial and cervical cancer patients treated in our
center, with similar multidisciplinary treatment approach.
Interestingly, this analysis is one of the first analyzing the
relationship between QoL and dosimetry values, in terms
of dose–volume parameters, among gynecologic cancer
survivors.
As stated by the PORTEC-2 study, QoL assessed in
follow-up can be correlated with toxicity occurred during
treatment [12]. In our experience, as reported in a previous
literature study [13], patients showed a good tolerance
profile, with no gastro-intestinal and genito-urinary acute
toxicity grade 3 or 4 according to RTOG scale, but no
correlation with QoL parameters assessed at later time
during follow-up.
From EORTC QLQ-C30, it emerged an overall good
profile of ‘‘global health.’’ It is likely that a recent cancer
diagnosis, performance of surgery and cancer symptoms
had negatively interfered with the perception of health
before treatment. As a result, there was a significant
improvement in QoL score for the question on general
health status.
QoL of gynecologic cancer patients tends to be worst
between time of diagnosis and completion of radiother-
apy, but it can improve during follow-up [14]. We con-
sidered a minimum follow-up time of 3.5 years to avoid
the potential confounding effect of immediate post-treat-
ment phase.
In our study, a low rate of gastro-intestinal complica-
tions (only 4 % of grade 3–4 abdominal pain) was reported,
while PORTEC-2 study showed an increase in abdominal
pain even years after treatment. In the same way, the
answers related to urinary symptoms pointed out no dis-
comforts, while other studies reported an increased inci-
dence of urinary incontinence and dysuria in particular in
patients treated with radiotherapy for cervical cancer [1].
These results should be related not only to radiotherapy but
also to surgery. Radical hysterectomy is characterized by
pelvic anatomic dislocation of ureters and excision of tis-
sues around vagina that could damage pelvic nerves with
reduction in bladder continence. All patients of our series
underwent similar surgical approaches, and we selected
patients, as pointed out in ‘‘Materials and methods’’ sec-
tion, with minimal surgical sequelae.
In our study, as well as in PORTEC-2, women were
generally quite reluctant to answer questions on sexual
activity. More than a half of patients (65.4 %) answering
these questions declared to be sexually active. The most
important symptom referred in our series was vaginal
dryness with painful intercourse (dyspareunia) and tight-
ening and/or shortening of the vagina, in particular in
patients treated with adjuvant EBRT. Previous studies
reported similar results: Vaz et al. [1] observed decreased
sexual interest (29.7 %) with dyspareunia (45.9 %), and
Jensen et al. [15] described vaginal dryness (35 %) and
painful intercourse (55 %). In our study, we found dys-
pareunia in 5.9 % of sexually active patients, but probably
this rate could be underestimated.
Sexual dysfunction from surgery is mainly caused by a
shortened vagina [16], vaginal dryness [16, 17] and
decreased libido [15, 17]. In contrast, sexual dysfunction
from radiotherapy is caused by vaginal stenosis, which
often yields dyspareunia, difficulty in orgasm, decrease in
sexual satisfaction and changes in body image [17]. In the
past, the results of studies concerning sexual function of the
cervical cancer patients had shown that the RT group had
worse sexual function than the surgery-alone group. In fact,
according to Jensen et al. [15, 16], 63 % of the women who
received RT and 91 % of those who received surgery had
been sexually active. These historical data are similar to
our findings.
An original aspect of our study is the correlation of
specific items of QoL questionnaires with dose–volume
parameters. We found a statistically significant correlation
between increasing bladder V40 and declined self-reported
QoL (item 30). Interestingly, a higher bladder V40 was
also correlated with an increased urgency and incontinence.
We considered patients with minor postoperative sequelae
with the purpose to evaluate more selectively the role of
adjuvant therapies, since several surgical studies showed
how dissection of parametria and upper vagina could
adversely affect autonomic innervations (S2–S4 levels)
after radical hysterectomy [4].
A recent publication compared the low urinary tract
dysfunctions between patients who received concurrent
chemoradiation and those who received radical hysterec-
tomy [18]. This study showed that storage dysfunction was
significantly more prevalent after adjuvant radiotherapy
than after radical hysterectomy alone. Despite the high
incidence of long-term urinary symptoms, QoL was mini-
mally affected, suggesting that these symptoms have mild
severity and minimal impact in survivors. In our experi-
ence, bladder V40 was statistically correlated with wors-
ening of global health status (p\ 0.05), but this parameter
alone can explain a relatively small proportion (17 %) of
QoL changes.
In our study, we found that only 14.6 % of patients had
bladder urgency after radiotherapy, while 3.1 % had uri-
nary incontinence. Interestingly, increasing in bladder V40
906 Clin Transl Oncol (2016) 18:901–908
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explained 24 % of these storage symptoms. From our
analysis, it emerged also a correlation between the mean
dose to vagina and urinary incontinence. We could explain
this fact considering that vagina is surrounded by pelvic
nerves that control bladder function and can be damaged by
high radiation doses.
From our analysis, it emerged that the increasing mean
dose to vagina was correlated with worsening of global
health status (p = 0.03). Probably, these data could be
related to urinary incontinence: in fact, patients with higher
mean doses to vagina present higher bladder discomfort
that could cause deterioration in self-reported global health
status.
Patients included in the present study referred only few
rectal discomforts after radiotherapy. A previous controlled
study suggested that bowel symptoms are more prevalent
in long-term survivors [19]. We can underline that the large
majority of our patients was treated with IMRT with
strictly respected dose constraints and that the relatively
low value of the average rectal volume (50.6 cc) would
indicate an adequate bowel preparation [7]. These factors
could have contributed to reduce the occurrence of late
rectal symptoms.
Radiation-induced damage on LSP in gynecologic can-
cers is a quite rare complication of pelvic irradiation. The
reported frequency ranges from 1.3 to 6.7 %, and the
clinical course is associated with different degrees of
bilateral lower limb pain, abdominal diffuse pain, numb-
ness, weakness, paresis or paralysis, and rarely, urinary or
fecal incontinence [20]. We found a statistically significant
correlation between LSP maximum dose and abdominal
pain without correlation with bladder or fecal symptoms.
LSP maximum dose alone explained a small proportion of
the variance in QoL with R2 value of 0.07. We should point
out that abdominal pain is an unspecific symptom and
could relate to multiple factors including radiotherapy as
observed in our experience.
Both radical surgery and postoperative radiotherapy can
have medium- and long-term impact on sexual functioning
among cervical cancer survivors as shown by other authors
who found that patients who received radiotherapy had a
significantly worse score in health-related QoL, psy-
chosocial distress, menopausal symptoms and sexual
functioning [21, 22]. In our study, we found that out of 85
patients answering questions related to sexual function
34.6 % was not sexually active. This value is similar to that
reported in other series [23]. According to our analysis,
only 5.9 % of sexually active patients referred deep dys-
pareunia. This value may contain an internal bias: in fact,
women with sexual activity most likely have no or minimal
vaginal discomforts (lack of vaginal elasticity and lack of
lubrification) [24]. Similarly, we could not assess how
many patients had sexual alterations in postoperative
setting, because no patient was sexually active in the
transition period between surgery and radiotherapy. In
agreement with our findings, a recent study showed that
patients after hysterectomy had persistent sexual dysfunc-
tions [25].
Gondi et al. [22] observed no demonstrable association
between dose–volume parameters and vaginal toxicity. In
our study, the significant correlation between bladder V40
and dyspareunia explained a very small proportion of
relation (R2 = 0.04). We should underline that sexual QoL
is related not only to treatments but also to psychological
and more general health factors.
Although to the best of our knowledge, this study is the
first that correlates QoL and radiation dose–volume
parameters in gynecologic cancer long survivors, it has
some limitations. QoL was not assessed before and after
surgery, and this fact could bias the results observed during
long-term follow-up by impairing to clearly distinguish
dysfunctions related to each single treatment modality.
Another limitation is the relatively low response rate
(65.4 %) to sexual function questions with respect to par-
ticipation in the overall study.
Conclusions
The present study shows that QoL of long-term survivors
after surgery and postoperative radiotherapy for endome-
trial and cervical cancer has a quite favorable profile.
From our analysis, it emerges that parameters related to
bladder function may be negatively affected by bladder
V40 and mean dose to vagina. Moreover, sexual function
can be worsened by bladder V40 and abdominal pain by
maximum dose to LSP.
Based on the available literature data and the present
study, radiation optimization should take more carefully
into account patients’ QoL after long-term follow-up, and
future prospective trials could further investigate the cor-
relation between specific QoL items and dose–volume
parameters in patients affected by gynecologic malignan-
cies undergoing surgery and adjuvant radiotherapy.
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